Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3251323 | 0.79 | MAPK14 (0.48) | KDM4ENPC1ALDH1A1GAANFKB1 | |
| SCHEMBL3254392 | 0.72 | MAPK14 (0.41) | KDM4ENPC1ALDH1A1GAANFKB1 | |
| SCHEMBL3251929 | 0.70 | MAPK14 (0.47) | KDM4ENPC1ALDH1A1GAANFKB1 | |
| SCHEMBL3249327 | 0.70 | MAPK9 (0.51) | KDM4ENPC1ALDH1A1GAANFKB1 | |
| SCHEMBL3253883 | 0.69 | MAPK9 (0.47) | KDM4ENPC1ALDH1A1GAANFKB1 | |
| SCHEMBL12467808 | 0.68 | KDM4E (0.51) | KDM4ENPC1ALDH1A1GAANFKB1 | |
| SCHEMBL3248737 | 0.66 | KDM4E (0.41) | KDM4ENPC1ALDH1A1GAANFKB1 | |
| SCHEMBL3252473 | 0.64 | GSK3A (0.40) | MAPK14MAPK9 | |
| SCHEMBL3250649 | 0.64 | MAPK9 (0.47) | NPC1RAB9ASMN1; SMN2MAPK14MAPK9 | |
| SCHEMBL13678697 | 0.62 | MAPK9 (0.49) | MAPK14MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833477-B1 | PYRAZOLO-HETEROARYL COMPOUNDS USEFUL TO TREAT TNF-ALPHA AND IL-1 MEDIATED DISEASES | NOVARTIS AG (CH) | 2010-06-02 | — | — | EP | claimed |